Longeveron (LGVN) Notes Payables (2021 - 2023)

Longeveron's (LGVN) quarterly Notes Payables came in at $457000.0 in Q1 2023, down 73.9% quarter-over-quarter from $1.8 million in Q4 2022.

Longeveron (LGVN) Notes Payables (2021 - 2023) Analysis & Trends

Longeveron's Notes Payables history runs 3 years deep, the most recent figure standing at $457000.0 for Q1 2023.

  • On a quarterly basis, Notes Payables changed N/A year-over-year to $457000.0 in Q1 2023; TTM through Mar 2023 was $457000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $1.8 million, up 171.47% from the prior year.
  • Notes Payables slipped to $457000.0 in Q1 2023 per LGVN's latest filing, from $1.8 million in the prior quarter.
  • Across five years, Notes Payables topped out at $1.8 million in Q4 2022 and bottomed at $457000.0 in Q1 2023.
  • The 3-year median for Notes Payables is $645000.0 (2021), against an average of $951000.0.
  • Biggest YoY gain for Notes Payables was 171.47% in 2022; the steepest drop was 171.47% in 2022.
  • Year by year, Notes Payables stood at $645000.0 in 2021, then jumped by 171.47% to $1.8 million in 2022, then plunged by 73.9% to $457000.0 in 2023.
  • Per Business Quant, the three latest LGVN Notes Payables figures stand at $457000.0 (Q1 2023), $1.8 million (Q4 2022), and $645000.0 (Q4 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00

Historic Data

Download Data
DateValue
Mar 31, 2023 457,000.00
Dec 31, 2022 1.75 Mn
Dec 31, 2021 645,000.00